This glossary provides brief explanations of terms used in the Ontario Public Drug Programs web pages. To access a term definition, select the appropriate letter from the alphabet below.
| DIDFA |
See Drug Interchangeability and Dispensing Fee Act
|
| Disease-free survival |
Time from clinical trial randomization until recurrence of disease or until death from any cause. Disease-free survival is sometimes used in clinical studies to assess the efficacy of a treatment, especially in situations where survival may be prolonged, making measurement of overall survival impractical. (See overall survival.) |
| Double-blind study |
A clinical trial designed so that neither the participating individuals nor the study staff knows which participants receive the experimental drug and which receive the placebo or standard of therapy. (See Placebo)
Blinding ensures that investigators' preferences or expectations, or participants' desire to please investigators or hope of improvement, does not influence and distort results. See single-blind.
|
| Drug Interchangeability and Dispensing Fee Act (DIDFA) |
The Drug Interchangeability and Dispensing Fee Act and its accompanying regulations, Ontario Regulations 935 and 936, govern the designation of drugs as interchangeable in the ODB Formulary. |
| Drug Quality and Therapeutics Committee (DQTC) |
Former name of the Committee to Evaluate Drugs. |
| Drug System Secretariat |
The Ministry of Health and Long-Term Care established the Drug System Secretariat at the direction of the Minister of Health and Long-Term Care to conduct an objective, system-wide review of Ontario’s entire drug system.
The Secretariat developed a package of recommendations to reform the provincial drug system. The recommendations consider five main areas: pricing and reimbursement of drug products; access to drug products; need for more appropriate use partnerships; innovation; and, strengthening the governance and operations of Ontario’s drug system.
The Drug System Secretariat has now become the Ontario Public Drug Programs Office.
|
Text Only Version
